The role of the Management Team and the four boards of the TI Pharma are detailed in the governance of the Institute

Transcription

1 Top Institute Pharma Governance and location 1 The role of the Management Team and the four boards of the TI Pharma are detailed in the governance of the Institute governance Supervisory Board () Executive Board () International Scientific Review Committee (ISRC) ((bi-)annual peer review) Managing Director () Research matrix of Themes & Disciplines Scientific Director () Board of Trustees (BoT) Academic representatives Industrial representatives 2

2 GOVERNANCE The Supervisory Board is the highest governing body of the Institute in which all partners are represented Supervisory Board Chair Representatives from all partners Independent, senior and reputed manager Not necessarily a pharmaceutical background Yearly, or special meetings on ad-hoc issues Voting Majority vote for industrial partners Supervise Executive Board Appoint Executive Board Approve strategic research plan Approve annual operating plan and budget 3 GOVERNANCE The Executive Board consists of representatives of all relevant functional groups and works closely with the Management Team Executive Board 7 representatives with a functional basis: large and small Industrial partners (4 chairs, including chairman), clinical and preclinical within Academia (3 chairs) Chair From an Industrial Main Founding Father At least 6 times per year Voting 7 votes: headcount, no replacement by absence Assist MT in preparing the annual research and operational plan Evaluate and monitor funding over individual projects Sounding board for the Institute Management Team Appoint Managing and Scientific Director Approve deviations of IP arrangements per project from general IP guidelines Approve individual projects 4

3 GOVERNANCE The Management Team consists of a Managing Director and Scientific Director who manage the Institute on a day to day basis MT Managing Director Industrial background, senior manager Scientific Director Senior professor with a very strong academic reputation Job Full time (tbd) Full time (tbd) (main tasks) Day to day management Prepare strategic plan, annual plan, incl. budget Prepare reporting to and Acquire new partners and funding Represent in the scientific community Attract world class scientists Monitor scientific quality of projects Develop high quality training program Monitor, steer and report adherence of projects with overall policies (including Priority Medicines) (main tasks) Appoint coordinators and headquarter staff Manage HQ infrastructure Manage project portfolio on a day to day basis (investments in small equipment, scientific issues ) 5 GOVERNANCE The International Scientific Review Committee reviews the performance and quality of the Institute on a (bi-)annual basis ISRC International Scientific Review Committee International well reputed representatives and professors from Industry and Academia, together with WHO (Priority Medicines, to be confirmed with government) (Bi-)annual peer review of the Institute including visits to the participating groups, Judgment on balance in project portfolio and overall quality Independent check on how is meeting its objectives, including on Priority Medicines Providing the MT and Executive Board of the with well founded recommendations 6

4 GOVERNANCE The Board of Trustees formalizes the role of s biggest partner, the society as a whole: Government, FIGON, ZonMw, BoT Board of Trustees Chair FIGON, funding ministries, ZonMw, CBG, patient organizations and European partners FIGON 2 times per year Liaise with Government and Executive Board Advise on opportunities for involvement of other institutes Advise Management Team and Exec. Board Stimulate European initiatives and collaborations Providing the MT and Executive Board of the with well founded recommendations 7 MEMBERS The Supervisory Board has seats for all Academic and Industrial partners and is chaired by dr. S. Noorda Chair: Dr. S. Noorda Members of the Supervisory Board Academic partners (incl. knowledge institutes) Universiteit Utrecht Vrije Universiteit Amsterdam Rijksuniversiteit Groningen Universiteit van Amsterdam Universiteit Leiden Radboud Universiteit Nijmegen Universiteit Maastricht Erasmus Universiteit Rotterdam TNO Kwaliteit van Leven Industrial partners Organon International Crucell Johnson & Johnson Solvay Pharmaceuticals Biomade Octoplus IQCorporation Pepscan systems Pharma Bio-research Numico Altana Fuji Photo Film Cardialysis GlaxoSmithKline Pharming 8

5 MEMBERS The Executive Board represents the large and small industrial partners as well as Academic research - and medical centers Proposed members of the Executive Board Chairman Dr. T. Rijnders Industrial members Prof.dr.med. L. Turski (large industry) A. Lahr (small industry) Dr. J. Holthuis (small industry) Academic members Prof.dr. L. de Leij (University Medical Centers background) Prof.dr. R. Leurs (preclinical research) Prof.dr. F. Russel (preclinical research) 9 MEMBERS The Management Team consists of Managing Director dr. V. Nicholson and Scientific Director prof.dr. D. Crommelin MT Managing Director Scientific Director Name Dr. V. Nickolson Prof.dr. D. Crommelin 10

6 LOCATION It has been decided that the Leiden Bio Science Park will house the headquarters of the Leiden Bio Science Park Reasons for housing in Leiden Accessibility, travel distance and working environment Pharmaceutical environment: image, close to working groups, both industrial and academic Positioned centrally in the Netherlands, close to airport and other facilities Close to (pharmaceutical) economic activity and nearby (biotech) startups Possibility to organize conferences and host foreign visitors Mutual benefit of visibility: both for the as well as the hosting city 11